PROCEPT BioRobotics Corporation
PRCTHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. With a market capitalization of $1.55B, it sits in small-cap territory. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
Market Cap
$1.55B
Beta
0.83
P/E (TTM)
—
P/E (Fwd)
-31.41
EPS (TTM)
$-1.83
EPS (Fwd)
$-0.87
ROE
-27.8%
ROA
-13.5%
Cash
$245.6M
Total Debt
$78.0M
Free CF
-$43.2M
52W Change
-53.1%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $245.6M in cash comfortably exceeding the $78.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$43.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -27.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $75.0M (2022) to $308.1M (2025), reflecting a 311% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PRCT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.